When treating low-risk primary basal cell carcinoma (BCC), surgery and external beam radiation yield a better chance of a cure and a lower recurrence rate compared with other treatment modalities.
Skin Cancer (Nonmelanoma)
Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation.
Individuals who develop frequent basal cell carcinomas may have an increased prevalence of germline mutations in DNA repair genes and an increased malignancy risk.
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.
In this article, we review the published literature and evaluate secondary prevention strategies for nonmelanoma skin cancer. We also explore investigational therapies proposed for chemoprevention of nonmelanoma skin cancers.
The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972.
Interventions can improve sun protection behaviors, but this does not necessarily correlate with skin cancer/melanoma outcomes, according to a review for the USPSTF.
An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.
The FDA on March 23, 2017, granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.
Treatment of keratinocyte carcinomas such as basal cell carcinoma and cutaneous squamous cell carcinoma with PD-1 checkpoint inhibitors and targeted agents warrant further investigation, according to recently published studies.